Cumberland Pharmaceuticals Inc (CPIX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CPIX SEC filings page.
Cumberland Pharmaceuticals Inc (CPIX) reported $39.9M in revenue over the twelve months to Jun 30, 2026, down 5.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 restored cash generation and narrowed losses, but a creditor-heavy balance sheet leaves little short-term financial cushion.
Operating cash flow swung from-$612K in FY2024 to$4.9M in FY2025, reversing the prior year's cash shortfall. Free cash flow likewise moved from-$679K to$4.8M , so the accounting loss coexisted with cash generation rather than mirroring the company's cash economics.
Revenue reached
Accounts receivable reached
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cumberland Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cumberland Pharmaceuticals Inc held $11.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $4.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Cumberland Pharmaceuticals Inc scores 86/100 among other emerging companies.
Cumberland Pharmaceuticals Inc had 15M shares outstanding at the end of fiscal year 2025, against 14M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Cumberland Pharmaceuticals Inc scores 63/100 among other emerging companies.
Cumberland Pharmaceuticals Inc spent $5.6M on research and development in fiscal year 2025, which was 11.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Cumberland Pharmaceuticals Inc scores 39/100 among other emerging companies.
Cumberland Pharmaceuticals Inc reported revenue of $44.5M in fiscal year 2025, against $37.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Cumberland Pharmaceuticals Inc scores 51/100 among other emerging companies.
Not available for Cumberland Pharmaceuticals Inc, and counted as zero in the overall score.
Cumberland Pharmaceuticals Inc's cash, cash equivalents and investments came to $11.4M at the end of fiscal year 2025, against $52.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Cumberland Pharmaceuticals Inc scores 28/100 among other emerging companies.
Cumberland Pharmaceuticals Inc scores 1.18, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($105.3M) relative to total liabilities ($52.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cumberland Pharmaceuticals Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Cumberland Pharmaceuticals Inc reported a net loss of $2.8M while generating $4.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Cumberland Pharmaceuticals Inc reported an operating loss of $2.8M against $496K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cumberland Pharmaceuticals Inc generated $8.8M in revenue in Q2 2026. This represents a decrease of 18.8% from the same quarter a year earlier. Against the prior quarter it is down 3.6%.
Cumberland Pharmaceuticals Inc's EBITDA was -$4.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.2% from the same quarter a year earlier. Against the prior quarter it is down 135.6%.
Cumberland Pharmaceuticals Inc reported -$4.3M in net income in Q2 2026. This represents a decrease of 477.3% from the same quarter a year earlier. Against the prior quarter it is down 30.0%.
Cumberland Pharmaceuticals Inc earned -$0.29 per diluted share (EPS) in Q2 2026. This represents a decrease of 480.0% from the same quarter a year earlier. Against the prior quarter it is down 31.8%.
Cash & Balance Sheet
Cumberland Pharmaceuticals Inc generated $130K in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 84.0% from the same quarter a year earlier. Against the prior quarter it is down 66.3%.
Cumberland Pharmaceuticals Inc held $3.9M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Cumberland Pharmaceuticals Inc's operating margin was -35.9% in Q2 2026, reflecting core business profitability. This is down 7.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.6 percentage points.
Cumberland Pharmaceuticals Inc's net profit margin was -48.6% in Q2 2026, showing the share of revenue converted to profit. This is down 41.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 12.6 percentage points.
Cumberland Pharmaceuticals Inc's ROE was -24.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 21.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.3 percentage points.
Not reported for Q2 2026.
Capital Allocation
Cumberland Pharmaceuticals Inc invested $772K in research and development in Q2 2026. This represents a decrease of 7.8% from the same quarter a year earlier. Against the prior quarter it is down 47.1%.
Cumberland Pharmaceuticals Inc repurchased no shares in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Cumberland Pharmaceuticals Inc invested $38K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 44.5% from the same quarter a year earlier.
CPIX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.8M-18.8% | $9.1M-22.0% | $13.7M+31.1% | $8.3M-8.7% | $10.8M+10.0% | $11.7M+37.8% | $10.4M+11.6% | $9.1M-9.9% |
| Cost of Revenue | N/A | $1.9M+35.6% | N/A | $989K-25.3% | $2.0M+17.6% | $1.4M-9.5% | N/A | $1.3M-25.1% |
| Gross Profit | N/A | $7.2M-30.0% | N/A | $7.3M-5.9% | $8.8M+8.5% | $10.3M+48.6% | N/A | $7.8M-6.7% |
| R&D Expenses | $772K-7.8% | $1.5M+12.6% | N/A | $1.3M-4.0% | $837K-20.9% | $1.3M+11.8% | N/A | $1.3M-32.1% |
| SG&A Expenses | $2.5M-4.1% | $2.6M+3.7% | N/A | $2.6M-3.9% | $2.7M-3.6% | $2.5M+4.0% | N/A | $2.7M+14.1% |
| Operating Income | -$3.2M-1.3% | -$3.1M-342.2% | -$1.4M+25.6% | -$2.0M-16.0% | -$3.1M-203.8% | $1.3M+169.1% | -$1.8M+70.2% | -$1.7M+9.2% |
| EBITDA | -$4.4M-7.2% | -$1.9M-179.7% | -$329K+4.7% | $1.1M+283.3% | -$4.1M-3712.5% | $2.3M+423.4% | -$346K+93.0% | -$578K+6.8% |
| Interest Expense | $724+53.7% | $86K-47.6% | N/A | $110K-20.1% | $471-99.6% | $164K+38.2% | N/A | $137K+24.8% |
| Income Tax | $4K-31.8% | $4K-31.7% | N/A | $6K-50.4% | $6K-50.4% | $6K-50.4% | N/A | $11K+64.9% |
| Net Income | -$4.3M-477.3% | -$3.3M-361.7% | -$1.4M+25.8% | -$1.9M-25.7% | -$741K+31.8% | $1.3M+164.6% | -$1.9M+69.8% | -$1.5M-47.2% |
| EPS (Basic) | -$0.29-480.0% | -$0.22-375.0% | -$0.09+35.7% | -$0.13-18.2% | -$0.05+37.5% | $0.08+157.1% | -$0.14+68.2% | -$0.11-57.1% |
| EPS (Diluted) | -$0.29-480.0% | -$0.22-375.0% | -$0.09+35.7% | -$0.13-18.2% | -$0.05+37.5% | $0.08+157.1% | -$0.14+68.2% | -$0.11-57.1% |
| Diluted Shares (Avg) | 15M+0.1% | 15M-2.0% | N/A | 15M+6.4% | 15M+6.0% | 15M+8.2% | N/A | 14M-1.6% |
CPIX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $62.9M-7.4% | $71.0M+1.5% | $76.8M+1.6% | $65.9M-14.1% | $67.9M-13.5% | $69.9M-14.2% | $75.6M-7.6% | $76.7M-12.5% |
| Current Assets | $33.6M+7.8% | $32.8M+2.9% | $37.1M+1.7% | $29.9M-15.0% | $31.2M-12.3% | $31.9M-12.0% | $36.5M+2.1% | $35.2M-15.6% |
| Cash & Equivalents | $3.9M-76.0% | $11.0M-27.1% | $11.4M-36.3% | $15.2M-13.0% | $16.1M-7.2% | $15.1M-18.5% | $18.0M-2.0% | $17.5M-5.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $30K-99.1% | $5.5M+33.1% | $30K-99.3% | $2.9M-34.9% | $3.2M-25.1% | $4.1M-5.3% | $4.0M-13.2% | $4.5M-48.0% |
| Accounts Receivable | $13.4M+30.1% | $14.3M+36.0% | $16.9M+44.8% | $10.4M-7.8% | $10.3M-11.2% | $10.5M-1.5% | $11.7M+19.9% | $11.3M-10.4% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | $914K0.0% | $914K0.0% | $914K0.0% | $914K0.0% | $914K0.0% | $914K0.0% | $914K0.0% |
| Total Liabilities | $45.8M+13.8% | $49.7M+19.5% | $52.3M-1.4% | $40.1M-23.3% | $40.2M-23.4% | $41.6M-23.4% | $53.0M+1.0% | $52.3M+0.4% |
| Current Liabilities | $35.2M+46.8% | $34.5M+35.1% | $36.7M+16.2% | $24.3M-21.8% | $24.0M-3.2% | $25.5M-3.4% | $31.6M+13.0% | $31.1M+13.8% |
| Non-Current Liabilities | $10.6M-34.9% | $15.2M-5.4% | $15.5M-27.5% | $15.8M-25.5% | $16.3M-41.4% | $16.1M-42.4% | $21.4M-12.7% | $21.2M-14.4% |
| Total Equity | $17.4M-37.7% | $21.6M-24.5% | $24.9M+8.9% | $26.1M+5.4% | $28.0M+6.2% | $28.7M+4.2% | $22.9M-22.8% | $24.8M-31.2% |
| Retained Earnings | -$34.4M-46.6% | -$30.1M-32.5% | -$26.8M-11.8% | -$25.4M-15.1% | -$23.5M-14.3% | -$22.7M-16.9% | -$24.0M-37.1% | -$22.1M-97.1% |
Not reported in any period shown, so not listed: Long-Term Debt.
CPIX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $169K-80.0% | $387K-90.1% | $3K-99.8% | $187K-60.6% | $844K+198.6% | $3.9M+282.5% | $1.9M+83.1% | $476K-61.5% |
| Depreciation & Amortization | -$1.2M-26.3% | $1.3M+23.7% | $1.0M-30.4% | $3.0M+171.1% | -$954K-183.7% | $1.0M-10.4% | $1.5M+21.3% | $1.1M-10.4% |
| Stock-Based Compensation | N/A | $107K+44.0% | N/A | N/A | N/A | $74K-5.8% | N/A | N/A |
| Capital Expenditures | $38K+44.5% | $0-100.0% | -$1-100.0% | $24K+54.7% | $26K+269.0% | $48K+14.4% | $2K-95.3% | $15K-71.1% |
| Free Cash Flow | $130K-84.0% | $387K-89.9% | $3K-99.8% | $163K-64.5% | $817K+194.7% | $3.9M+276.8% | $1.9M+91.9% | $460K-61.1% |
| Investing Cash Flow | -$1.9M-773.9% | -$61K+95.0% | -$3.1M-11363.8% | -$691K-464.3% | $286K+710.8% | -$1.2M-2010.8% | -$27K-110.3% | $190K+299.5% |
| Financing Cash Flow | -$5.4M-3472.5% | -$763K+86.2% | -$682K+50.5% | -$387K+27.9% | -$151K+51.3% | -$5.5M-328.2% | -$1.4M+7.3% | -$537K+39.2% |
| Share Buybacks | $0-100.0% | $61K-75.2% | $0-100.0% | $10K-89.4% | $7K-94.7% | $246K-0.7% | $98K-47.9% | $99K-51.0% |
Not reported in any period shown, so not listed: Dividends Paid.
CPIX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 78.8%-9.0pp | N/A | 88.1%+2.6pp | 81.4%-1.2pp | 87.8%+6.4pp | N/A | 85.4%+3.0pp |
| Operating Margin | -35.9%-7.1pp | -34.3%-45.3pp | -10.0%+7.6pp | -23.7%-5.0pp | -28.8%-18.4pp | 11.0%+33.0pp | -17.6%+48.4pp | -18.6%-0.1pp |
| Net Margin | -48.6%-41.8pp | -36.0%-46.8pp | -10.3%+7.9pp | -23.4%-6.4pp | -6.8%+4.2pp | 10.7%+33.6pp | -18.2%+49.1pp | -17.0%-6.6pp |
| Return on Equity | -24.5%-21.9pp | -15.2%-19.6pp | -5.7%+2.7pp | -7.4%-1.2pp | -2.6%+1.5pp | 4.4%+11.5pp | -8.3%+12.9pp | -6.2%-3.3pp |
| Return on Assets | -6.8%-5.7pp | -4.6%-6.4pp | -1.8%+0.7pp | -2.9%-0.9pp | -1.1%+0.3pp | 1.8%+4.2pp | -2.5%+5.2pp | -2.0%-0.8pp |
| Current Ratio | 0.96-0.3x | 0.95-0.3x | 1.01-0.1x | 1.23+0.1x | 1.30-0.1x | 1.25-0.1x | 1.15-0.1x | 1.13-0.4x |
| Debt-to-Equity | 2.62+1.2x | 2.30+0.8x | 2.10-0.2x | 1.54-0.6x | 1.44-0.6x | 1.45-0.5x | 2.32+0.5x | 2.11+0.7x |
| Asset Turnover | 0.140.0x | 0.130.0x | 0.180.0x | 0.130.0x | 0.160.0x | 0.17+0.1x | 0.140.0x | 0.120.0x |
| FCF Margin | 1.5%-6.1pp | 4.2%-28.6pp | 0.0%-18.2pp | 2.0%-3.1pp | 7.5%+16.3pp | 32.9%+58.5pp | 18.2%+7.6pp | 5.1%-6.7pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cumberland Pharmaceuticals Inc CPIX | FY2025 | $44.5M | -$2.8M | -6.4% | $105.3M | 45/100 |
| Durect Corp DRRX | FY2024 | $2.0M | -$8.3M | N/A | $59.3M | 45/100 |
| Rockwell Medical, Inc. (DE) RMTI | FY2025 | $69.3M | -$5.3M | -7.7% | $31.8M | 54/100 |
| Assertio Holdings, Inc. ASRT | FY2025 | $118.7M | -$30.4M | -25.6% | $151.9M | 37/100 |
Where Cumberland Pharmaceuticals Inc Ranks
Frequently Asked Questions
What is Cumberland Pharmaceuticals Inc's annual revenue?
Cumberland Pharmaceuticals Inc (CPIX) reported $44.5M in total revenue for fiscal year 2025. This represents a 17.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cumberland Pharmaceuticals Inc's revenue growing?
Cumberland Pharmaceuticals Inc (CPIX) revenue grew by 17.6% year-over-year, from $37.9M to $44.5M in fiscal year 2025.
Is Cumberland Pharmaceuticals Inc profitable?
No, Cumberland Pharmaceuticals Inc (CPIX) reported a net income of -$2.8M in fiscal year 2025, with a net profit margin of -6.4%.
What is Cumberland Pharmaceuticals Inc's EBITDA?
Cumberland Pharmaceuticals Inc (CPIX) had EBITDA of $1.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cumberland Pharmaceuticals Inc's gross margin?
Cumberland Pharmaceuticals Inc (CPIX) had a gross margin of 85.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cumberland Pharmaceuticals Inc's operating margin?
Cumberland Pharmaceuticals Inc (CPIX) had an operating margin of -6.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cumberland Pharmaceuticals Inc's net profit margin?
Cumberland Pharmaceuticals Inc (CPIX) had a net profit margin of -6.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cumberland Pharmaceuticals Inc's return on equity (ROE)?
Cumberland Pharmaceuticals Inc (CPIX) has a return on equity of -11.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cumberland Pharmaceuticals Inc's free cash flow?
Cumberland Pharmaceuticals Inc (CPIX) generated $4.8M in free cash flow during fiscal year 2025. This represents a 812.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cumberland Pharmaceuticals Inc's operating cash flow?
Cumberland Pharmaceuticals Inc (CPIX) generated $4.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cumberland Pharmaceuticals Inc's total assets?
Cumberland Pharmaceuticals Inc (CPIX) had $76.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cumberland Pharmaceuticals Inc's capital expenditures?
Cumberland Pharmaceuticals Inc (CPIX) invested $98K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cumberland Pharmaceuticals Inc spend on research and development?
Cumberland Pharmaceuticals Inc (CPIX) invested $5.6M in research and development during fiscal year 2025.
What is Cumberland Pharmaceuticals Inc's current ratio?
Cumberland Pharmaceuticals Inc (CPIX) had a current ratio of 1.01 as of fiscal year 2025, which is considered adequate.
What is Cumberland Pharmaceuticals Inc's debt-to-equity ratio?
Cumberland Pharmaceuticals Inc (CPIX) had a debt-to-equity ratio of 2.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cumberland Pharmaceuticals Inc's return on assets (ROA)?
Cumberland Pharmaceuticals Inc (CPIX) had a return on assets of -3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cumberland Pharmaceuticals Inc's P/E ratio?
Cumberland Pharmaceuticals Inc (CPIX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $105.3M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cumberland Pharmaceuticals Inc's price-to-sales ratio?
Cumberland Pharmaceuticals Inc (CPIX) trades at 2.6x sales, its market capitalization divided by revenue of $39.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $105.3M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cumberland Pharmaceuticals Inc's Altman Z-Score?
Cumberland Pharmaceuticals Inc (CPIX) has an Altman Z-Score of 1.18, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cumberland Pharmaceuticals Inc's Piotroski F-Score?
Cumberland Pharmaceuticals Inc (CPIX) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cumberland Pharmaceuticals Inc's earnings high quality?
Cumberland Pharmaceuticals Inc (CPIX) reported a net loss of $2.8M while generating $4.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cumberland Pharmaceuticals Inc cover its interest payments?
Cumberland Pharmaceuticals Inc (CPIX) reported an operating loss of $2.8M against $496K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Cumberland Pharmaceuticals Inc?
Cumberland Pharmaceuticals Inc (CPIX) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.